REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 14
- Part 14: For the preceding part double click ID:nRSH4027Rm
establish and defend robust patent protection for our products, we may
not succeed in protecting or enforcing our patents in such litigation or
other challenges.We bear the risk that courts may decide that third
parties do not infringe our asserted IP rights. This may result in
AstraZeneca losing exclusivity and/or erosion of revenues.Where we assert
our IP rights but are ultimately unsuccessful, third parties may seek
damages, alleging, for example, that they have been inappropriately
restrained from entering the market. In such cases, we bear the risk that
we incur liabilities to those third parties.We also bear the risk that we
may be found to infringe patents owned or licensed exclusively by third
parties, including research-based and generic pharmaceutical companies
and individuals. Third parties may seek damages for alleged patent
- More to follow, for following part double click ID:nRSH4027RoRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement